Development and Clinical Validation of Early-stage Lung Cancer Prognostic Kit

Launched by CHUNG SHAN MEDICAL UNIVERSITY · Sep 23, 2022

Keywords

ClinConnect Summary

This clinical trial is focused on developing and testing a new tool to help predict the risk of recurrence in patients with early-stage lung cancer. Lung cancer is a serious disease, and even patients diagnosed at an early stage can face challenges, as some may experience a return of the cancer. Researchers have discovered specific markers in the tumors of patients that can help identify those who are at a higher risk for recurrence. The goal of this trial is to validate these markers and create two new kits: one for testing tumor samples and another for non-invasive blood tests.

To participate in this trial, individuals must be at least 20 years old and have been diagnosed with lung adenocarcinoma, a type of lung cancer. They should have had surgery to remove their tumors and be in good overall health. Participants will need to provide samples of their tumor tissue and possibly blood or other fluids for testing. Throughout the trial, they can expect to be closely monitored, and their health will be assessed regularly. This research is important as it aims to improve how we predict and manage lung cancer, ultimately helping to provide better care for patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Willing to sign and provide subject consent.
• • Male or female of age 20 or older.
• • Patients diagnosed with lung adenocarcinoma by tumor pathology.
• • Lung cancer with the pathological stage of IA/IB/II/IIIA according to the American Joint Committee on Cancer Staging Manual (8th Edition).
• • Complete tumor resection (R0 resection).
• • The East Coast Cancer Clinical Research Collaborative (ECOG) performance status was 0 or 1 at the time of grouping.
• • Those willing to provide tumor tissue or cytology specimens (including surgical specimens, tissue biopsy specimens, or cytology specimens), blood and body fluid specimens (for follow-up or disease recurrence, such as urine, malignant pleural effusion, ascites, pericardial fluid, etc.).
• Exclusion Criteria:
• • Not primary lung cancer patients.
• • Lung cancer patients whose pathological stage is not IA/IB/II/IIIA according to the American Joint Committee on Cancer Staging Manual (8th Edition) after surgery.
• • Patients with uncontrolled malignant tumors other than lung cancer.
• • Uncontrolled systemic disease (such as diabetes, hypertension, active infection, etc.) (determined by the principal investigator )
• • Pregnant women.
• • Any condition may put the patient at serious risk, may affect the interpretation of the trial results, or may seriously interfere with the patient's participation in the trial.